Abstract
Purpose
Clostridium difficile infection (CDI) prevention is particularly important for cancer patients, because diarrhea often results in dose reductions or delays of chemotherapy or radiotherapy. We conducted this study to better ascertain the incidence, susceptibility, and risk factors for CDI in cancer patients receiving chemotherapy at our hospital.
Methods
We performed a retrospective study among adult cancer patients admitted at “12 de Octubre” University Hospital between January 2009 through April 2013 who were diagnosed with diarrhea. Inpatient data were available on hospital medical records. We screened by immunochromatography system detecting glutamate dehydrogenase antigen, and C. difficile toxins A and B. Later, a polymerase chain reaction for detecting toxin B gene was performed.
Results
A total of 225 patients were included in the study, and 39 of them (17.3 %) were diagnosed with CDI. Type of tumor significantly differed between CDI patients, thus relative risk in each type of cancer was calculated after adjusting for age, antibiotic exposure, corticosteroid, and proton-pump inhibitor use. Patients with gastrointestinal tumors were less prone to CDI. Conversely, breast cancer patients have a greater predisposition to CDI. Antibiotic treatment was found to be associated with an increasing risk for CDI in breast cancer patients. Curiously, exposure to proton-pump inhibitors appeared protective in our cohort, except for lung cancer patients. However, we have not been able to find an association between a particular type of chemotherapy and CDI.
Conclusions
We underscore the urgent need for early recognition and diagnosis of CDI in cancer patients. Our findings indicate a probable association between antibiotic use and CDI incidence, at least in certain cancer, such as breast cancer.
Similar content being viewed by others
References
Eyre DW, Cule ML, Wilson DJ, Griffiths D, Vaughan A, O’Connor L et al (2013) Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med 369:1195–1205. doi:10.1056/NEJMoa1216064
Khan A, Raza S, Batul SA, Khan M, Aksoy T, Baig MA, Berger BJ (2012) The evolution of Clostridium difficile infection in cancer patients: epidemiology, pathophysiology, and guidelines for prevention and management. Recent Pat Antiinfect Drug Discov 7:157–170
Lipp MJ, Nero DC, Callahan MA (2012) Impact of hospital-acquired Clostridium difficile. J Gastroenterol Hepatol 27:1733–1737. doi:10.1111/j.1440-1746.2012.07242.x
Karas JA, Enoch DA, Aliyu SH (2010) A review of mortality due to Clostridium difficile infection. J Infect 61:1–8. doi:10.1016/j.jinf.2010.03.025
Mezoff EA, Cohen MB (2013) Acid suppression and the risk of Clostridium difficile infection. J Pediatr 163:627–630. doi:10.1016/j.jpeds.2013.04.047
Kim JS, Ward KK, Shah NR, Saenz CC, McHale MT, Plaxe SC (2013) Excess risk of Clostridium difficile infection in ovarian cancer is related to exposure to broad-spectrum antibiotics. Support Care Cancer 21:3103–3107. doi:10.1007/s00520-013-1888-2
Kelly CP, LaMont JT (2008) Clostridium difficile — more difficult than ever. N Engl J Med 359:1932–1940. doi:10.1056/NEJMra0707500
Cornely OA, Miller MA, Fantin B, Mullane K, Kean Y, Gorbach S (2013) Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol 31:2493–2499. doi:10.1200/JCO.2012.45.5899
Zwielehner J, Lassl C, Hippe B, Pointner A, Switzeny OJ, Remely M, Kitzweger E, Ruckser R, Haslberger AG (2011) Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting. PLoS One 6:e28654. doi:10.1371/journal.pone.0028654
Morotomi N, Fukuda K, Nakano M, Ichihara S, Oono T, Yamazaki T, Kobayashi N, Suzuki T, Tanaka Y, Taniguchi H (2011) Evaluation of intestinal microbiotas of healthy Japanese adults and effect of antibiotics using the 16S ribosomal RNA gene based clone library method. Biol Pharm Bull 34:1011–1020
Stringer AM, Gibson RJ, Bowen JM, Keefe DM (2009) Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab 10:79–83
van Vliet MJ, Harmsen HJ, de Bont ES, Tissing WJ (2010) The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog 6:e1000879. doi:10.1371/journal.ppat.1000879
Raza S, Baig MA, Russell H, Gourdet Y, Berger BJ (2010) Clostridium difficile infection following chemotherapy. Recent Pat Antiinfect Drug Discov 5:1–9
Bishop KD, Castillo JJ (2012) Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia. Leuk Lymphoma 53:1617–1619. doi:10.3109/10428194.2012.654472
Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N et al (2011) Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 365:1693–1703. doi:10.1056/NEJMoa1012413
Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079–1084. doi:10.1016/S0140-6736(05)67420-X
Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, Sadowsky MJ, Khoruts A (2014) Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol 306:G310–G319. doi:10.1152/ajpgi.00282.2013
Deshpande A, Pant C, Pasupuleti V, Rolston DD, Jain A, Deshpande N, Thota P, Sferra TJ, Hernandez AV (2012) Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 10:225–233. doi:10.1016/j.cgh.2011.09.030
Nesher L, Rolston KV (2013) Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy. Clin Infect Dis 56:711–717. doi:10.1093/cid/cis998
Stewart DB, Yacoub E, Zhu J (2012) Chemotherapy patients with C. difficile colitis have outcomes similar to immunocompetent C. difficile patients. J Gastrointest Surg 16:1566–1572. doi:10.1007/s11605-011-1783-4
Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B (2009) Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 30:253–264. doi:10.1111/j.1365-2036.2009.04037.x
Orellana-Miguel MA, Alcolea-Medina A, Barrado-Blanco L, Rodriguez-Otero J, Chaves-Sanchez F (2013) Algorithm proposal based on the C. Diff Quik Chek Complete ICT device for detecting Clostridium difficile infection. Enferm Infecc Microbiol Clin 31:97–99. doi:10.1016/j.eimc.2012.01.003
Stein A, Voigt W, Jordan K (2010) Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2:51–63. doi:10.1177/1758834009355164
Hautmann MG, Hipp M, Kolbl O (2011) Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment? Radiat Oncol 6:89. doi:10.1186/1748-717X-6-89
Hwang KE, Hwang YR, Seol CH, Park C, Park SH, Yoon KH, Park DS, Lee MK, Jeong ET, Kim HR (2013) Clostridium difficile infection in lung cancer patients. Jpn J Infect Dis 66:379–382
Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK (2012) Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 107:1011–1019. doi:10.1038/ajg.2012.108
Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN (2012) Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 107:1001–1010. doi:10.1038/ajg.2012.179
Reimer C (2013) Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol 27:443–454. doi:10.1016/j.bpg.2013.06.001
Heidelbaugh JJ, Metz DC, Yang YX (2012) Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? Int J Clin Pract 66:582–591. doi:10.1111/j.1742-1241.2012.02921.x
Chopra T, Alangaden GJ, Chandrasekar P (2010) Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther 8:1113–1119. doi:10.1586/eri.10.95
Baier R, Morphis B, Marsella M, Mermel LA (2013) Clostridium difficile surveillance: a multicenter comparison of LabID events and use of standard definitions. Infect Control Hosp Epidemiol 34:653–655. doi:10.1086/670642
Conflict of interest
The authors have no conflicts of interest to disclose.
The authors have had full control of all primary data for the study, and they agree to allow the journal to review their data if requested.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rodríguez Garzotto, A., Mérida García, A., Muñoz Unceta, N. et al. Risk factors associated with Clostridium difficile infection in adult oncology patients. Support Care Cancer 23, 1569–1577 (2015). https://doi.org/10.1007/s00520-014-2506-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-014-2506-7